Menu
GWAS Study

Shared genetic risk factors across carbamazepine-induced hypersensitivity reactions.

Nicoletti P, Barrett S, McEvoy L et al.

31066027 PubMed ID
GWAS Study Type
8450 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

NP
Nicoletti P
BS
Barrett S
ML
McEvoy L
DA
Daly AK
AG
Aithal G
LM
Lucena MI
AR
Andrade RJ
WM
Wadelius M
HP
Hallberg P
SC
Stephens C
BE
Bjornsson ES
FP
Friedmann P
KK
Kainu K
LT
Laitinen T
MA
Marson A
MM
Molokhia M
PE
Phillips E
PW
Pichler W
RA
Romano A
SN
Shear N
SG
Sills G
TL
Tanno LK
SA
Swale A
FA
Floratos A
SY
Shen Y
NM
Nelson MR
WP
Watkins PB
DM
Daly MJ
MA
Morris AP
AA
Alfirevic A
PM
Pirmohamed M
Chapter II

Abstract

Summary of the research findings

Carbamazepine (CBZ) causes life-threating T-cell-mediated hypersensitivity reactions, including serious cutaneous adverse reactions (SCARs) and drug-induced liver injury (CBZ-DILI). In order to evaluate shared or phenotype-specific genetic predisposing factors for CBZ hypersensitivity reactions, we performed a meta-analysis of two genomewide association studies (GWAS) on a total of 43 well-phenotyped Northern and Southern European CBZ-SCAR cases and 10,701 population controls and a GWAS on 12 CBZ-DILI cases and 8,438 ethnically matched population controls. HLA-A*31:01 was identified as the strongest genetic predisposing factor for both CBZ-SCAR (odds ratio (OR) = 8.0; 95% CI 4.10-15.80; P = 1.2 × 10-9 ) and CBZ-DILI (OR = 7.3; 95% CI 2.47-23.67; P = 0.0004) in European populations. The association with HLA-A*31:01 in patients with SCAR was mainly driven by hypersensitivity syndrome (OR = 12.9; P = 2.1 × 10-9 ) rather than by Stevens-Johnson syndrome/toxic epidermal necrolysis cases, which showed an association with HLA-B*57:01. We also identified a novel risk locus mapping to ALK only for CBZ-SCAR cases, which needs replication in additional cohorts and functional evaluation.

12 European ancestry cases, 8,438 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

8450
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.K.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.